老年转移性恶性肿瘤患者衰弱的多学科管理

doi:10.3969/j.issn.1003-9198.2026.10.002

摘要/Abstract

摘要： 衰弱是老年转移性恶性肿瘤患者中普遍存在的临床状态,表现为多系统生理储备下降和应激易感性增加。衰弱不仅可独立预测化疗毒性、术后并发症、功能衰退和死亡风险,还可能导致治疗不足与过度治疗并存的决策困境。本文系统综述了衰弱的理论基础与评估工具、衰弱对老年转移性恶性肿瘤患者预后的影响,以及基于老年综合评估的多学科管理策略,旨在为临床实践中老年转移性恶性肿瘤患者的个体化治疗与全程管理提供参考依据。

关键词: 老年人, 肿瘤转移, 衰弱, 多学科管理, 老年综合评估

Abstract: Frailty is a prevalent clinical condition among elderly patients with metastatic malignant tumors, characterized by a decline in multisystem physiological reserve and increased vulnerability to stressors. Frailty not only independently predicts chemotherapy toxicity, postoperative complications, functional decline, and mortality risk, but may also lead to a therapeutic dilemma in which both undertreatment and overtreatment coexist. This article systematically reviews the theoretical foundations and assessment tools of frailty, the impact of frailty on the prognosis of elderly patients with metastatic malignant tumors, and multidisciplinary management strategies based on comprehensive geriatric assessment, aiming to provide a reference for individualized treatment and holistic care of elderly patients with metastatic malignant tumors in clinical practice.

Key words: aged, neoplasm metastasis, frailty, multidisciplinary management, comprehensive geriatric assessment

中图分类号:

R73
R592

朱丹, 韩云霞, 沈海瑞, 王伟, 赵坤. 老年转移性恶性肿瘤患者衰弱的多学科管理[J]. 实用老年医学, 2026, 40(10): 980-986.

ZHU Dan, HAN Yunxia, SHEN Hairui, WANG Wei, ZHAO Kun. Multidisciplinary management of frailty in elderly patients with metastatic malignant tumors[J]. Practical Geriatrics, 2026, 40(10): 980-986.

参考文献

[1] DE SCHREVEL J, FAUCON C, SIBILLE F X, et al. The Edmonton Frail Scale as a screening score for frailty in oncogeriatrics[J]. Front Med, 2024, 11: 1466366.
[2] HERNÁNDEZ-AGUIAR Y, BECERRA-BOLAÑOS Á, RODRÍGUEZ-PÉREZ A. Frailty and oncology: an increasingly common combination[J]. Cancer Med, 2026, 15(1): e71499.
[3] 王海, 朱银维, 韦小俞, 等. 以社区为基础多学科联合管理对老年人衰弱的影响研究[J]. 重庆医学, 2025, 54(S2): 163-165.
[4] TANG K S, FAN W. Beyond the sum of their parts: frailty and cardiometabolic disease in predicting mortality[J]. JACC Asia, 2025, 5(9): 1168-1170.
[5] DENT E, HANLON P, KOWAL P, et al. Frailty measurement in research and clinical practice:an updated review[J]. Eur J Intern Med, 2026, 144: 106595.
[6] CUI P, LI X, HUANG C, et al. Metabolomics-driven discovery of therapeutic targets for cancercachexia[J]. J Cachexia Sarcopenia Muscle, 2024, 15(3): 781-793.
[7] XU B, LIU J, ZHANG Y, et al. Impact of skeletal muscle loss and sarcopenia on outcomes of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma[J]. Front Nutr, 2025, 12: 1650337.
[8] MALLARD J, HUCTEAU E, BENDER L, et al. A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients[J]. J Cachexia Sarcopenia Muscle, 2024, 15(1): 292-305.
[9] OGUNSOLA O, HARAKE E S, SMITH S, et al. The dynamic nature of frailty in metastatic spine disease patients[J]. J Neurooncol, 2025, 175(3): 1247-1259.
[10] GIGER A W, DITZEL H M, EWERTZ M, et al. Effect of comprehensive geriatric assessment on hospitalizations in older adults with frailty initiating curatively intended oncologic treatment: the PROGNOSIS-RCT study[J].J Geriatr Oncol, 2024, 15(7): 101821.
[11] BONNEAU M, STEINMEYER Z, MORISSEAU M, et al. Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients[J]. BMC Cancer, 2025, 25(1): 642.
[12] KATSUTA T, NISHIBUCHI I, FUJIOKA M, et al. Association between Geriatric 8(G8) scores and self-care decline in elderly patients with head and neck squamous cell carcinoma undergoing radiotherapy[J]. Support Care Cancer, 2025, 33(10): 855.
[13] AARØNES T R, TARALDSEN K, PRIPP A H, et al. The Edmonton frail scale: a feasibility study on assessing frailty among older adults with multimorbidity in Norwegian primary health care[J]. BMC Prim Care, 2025, 26(1): 289.
[14] HORIUCHI K, KUNO T, TAKAGI H, et al. Predictive value of the Cancer and Aging Research Group Score for chemotherapy toxicities in older adults with cancer: a systematic review and meta-analysis[J]. Support Care Cancer, 2026: 34(2):85.
[15] FLETCHER J, REID N, HUBBARD R E, et al. Frailty index, not age, predicts treatment outcomes and adverse events for older adults with cancer[J].J Frailty Aging, 2024, 13(4): 487-494.
[16] LEEH J Jr, BOSCARDIN J, WALTER L C, et al. Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer[J]. Oncologist, 2025, 30(8): oyae349.
[17] HARBECK N, BRUFSKY A, GRACE ROSE C, et al. Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2-advanced/metastatic breast cancer: an updated systematic literature review[J]. Front Oncol, 2025, 15: 1577075.
[18] MATSUO T, KANDA Y, SAKAI Y, et al. Modified frailty index as a novel predictor for the incidence and severity of postoperative complications after spinal metastases surgery[J]. Bone Joint J, 2024, 106-B(12): 1469-1476.
[19] ELSAMADICY A A, SERRATO P, SADEGHZADEH S, et al. Assessing a revised-risk analysis index for morbidity and mortality after spine surgery for metastatic spinal tumors[J]. J Neurooncol, 2025, 171(1):213-228.
[20] TSUJIMOTO T, MATSUO T, YURUBE T, et al. Relationships between frailty and surgical outcomes of palliative surgery for spinal metastases: a prospective cohort study[J]. Bone Jt Open, 2025, 6(10): 1199-1207.
[21] DOUBLET S, PAGÈS A, THOMAS Z A, et al. Systemic treatment among frail older patients with cancer:an observational cohort[J]. J Geriatr Oncol, 2025, 16(2): 102177.
[22] OZLUK A A, WILLIAMS G R, DAI C, et al. Association between frailty and overall survival among older adults with hepatocellular carcinoma[J].J Geriatr Oncol, 2024, 15(7): 102045.
[23] 孟英涛, 王格, 尚美美, 等. 基于潜在剖面分析的老年癌症患者衰弱水平影响因素研究[J]. 中华肿瘤防治杂志, 2024, 31(20): 1252-1258.
[24] HSU C C, HUNG Y S, YU S M, et al. Integrating frailty assessment to enhance care in cancer patients with borderline eastern cooperative oncology group performance status[J]. Am J Hosp Palliat Care, 2024, 41(11): 1272-1279.
[25] PEARCE J, MARTIN S, HERITAGE S, et al. Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2025, 117(7): 1316-1339.
[26] JERJES W. Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy[J/OL]. Expert Rev Anticancer Ther, 2026: 1-3. https://doi.org/10.1080/14737140.2026.2673105.
[27] TROVATO G, SALVATORE L, TORTORA G. Response to letter to the editor: Geriatric assessment and sarcopenia in pancreatic cancer: toward personalized treatment beyond chronological age[J].J Geriatr Oncol, 2026, 17(2): 102890.
[28] LAMY T, PAGES A, THOMAS Z A, et al. Impact of a dedicated geriatric oncology tumor-board on therapeutic decision-making in patients aged 70 and over with cancer: the OncoBoardAge study[J]. J Geriatr Oncol, 2025, 16(8): 102433.
[29] SUN Y, TIAN Y, CAO S, et al. Supervised multimodal prehabilitation and clinical outcomes in older patients with frailty and gastric cancer:the GISSG+2201 randomized clinical trial[J]. JAMA Surg, 2026: 161(3):223-233.
[30] SEMENKOV A V, TULSKIKH D A, MELNIKOVA E A, et al. Preoperative multimodal prehabilitation in abdominal oncology[J]. Khirurgiia: Mosk, 2026(7):74-80.
[31] STEFFENS D, HANCOCK M, JIANG W, et al. An updated systematic review and meta-analysis of unimodal prehabilitation with exercise intervention to enhance postoperative outcomes in cancer surgery[J]. Anesth Analg, 2025, 140(4): 811-820.
[32] SINGHAL S, WANG Y, DUNNE R F, et al. Nutritional impairment and quality of life trajectories among older adults with advanced cancer[J]. J Am Geriatr Soc, 2025, 73(9): 2789-2797.
[33] WANG Y, LIU Y, CHENG L, et al. Effects of 12-week dietary inflammatory index-based dietary education on frailty status in frail patients with colorectal cancer: a randomized controlled trial[J]. Nutrients, 2025, 17(13): 2203.
[34] HSUEH S W, LAI C C, HUNG C Y, et al. A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in predicting treatment incompletion of concurrent chemoradiotherapy in patients with head and neck cancer[J]. Support Care Cancer, 2021, 29(9): 5455-5462.
[35] PEYRACHON R, LIÈVRE A, RÉBILLARD A. The role of aerobic and resistance exercise for cancer cachexia management-a systematic scoping review[J]. Asia Pac J Oncol Nurs, 2025, 12: 100748.
[36] WONDM S A, MOGES T A, DAGNEW S B, et al. Polypharmacy and potentially inappropriate medicine use in older adults with cancer: a multicenter cross-sectional study in Northwest Ethiopia oncologic centers[J]. J Pharm Policy Pract, 2024, 17(1): 2397797.
[37] LA J, HSHIEH T, HAMPARSUMIAN A, et al. Potentially inappropriate medications, frailty, and outcomes in patients with cancer managed in a national health care system[J]. J Natl Compr Canc Netw, 2025, 23(9): 363-370.
[38] GONG I Y, VIJENTHIRA A, ANTE Z, et al. Association of polypharmacy and potentially inappropriate medications with outcomes in older adults with DLBCL:a population study[J]. J Natl Compr Canc Netw, 2025, 23(8): e257029.